In this segment of the weekly health-care show, analyst David Williamson explains why investors need to have Arena Pharmaceuticals (ARNA) on their radar. Watch and find out how a big EU approval decision, DEA scheduling, and the first quarter sales report of competitor Vivus's (VVUS) Qsymia could impact the stock in the coming weeks.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Why Arena Pharmaceuticals should be on your radar.
Brenton Flynn has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.
The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Arena Pharmaceuticals
ARNA
VIVUS
VVUS
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
3 Absurdly Cheap Growth Stocks to Load Up On Right Now
Should You Buy Johnson & Johnson Stock Before July 16th?
Opinion: It's Time to Load Up on This Biotech Giant After Its 80% Crash
Most Investors Are Not Ready for What's About to Happen
This Stock Has Increased 4,720%: Here's Why It's Still a Buy
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.